326 related articles for article (PubMed ID: 16886645)
41. Serum tartrate-resistant acid phosphatase 5b activity as a prognostic marker of survival in breast cancer with bone metastasis.
Wu YY; Janckila AJ; Ku CH; Yu CP; Yu JC; Lee SH; Liu HY; Yam LT; Chao TY
BMC Cancer; 2010 Apr; 10():158. PubMed ID: 20416078
[TBL] [Abstract][Full Text] [Related]
42. Validity of bone marker measurements for monitoring response to bisphosphonate therapy with zoledronic acid in metastatic breast cancer.
Aktas B; Kasimir-Bauer S; Lehmann N; Kimmig R; Tewes M
Oncol Rep; 2013 Jul; 30(1):441-7. PubMed ID: 23604361
[TBL] [Abstract][Full Text] [Related]
43. Bone remodeling markers in the detection of bone metastases in prostate cancer.
de la Piedra C; Castro-Errecaborde NA; Traba ML; Méndez-Dávila C; García-Moreno C; Rodriguez de Acuña L; Rodriguez-Molina J
Clin Chim Acta; 2003 May; 331(1-2):45-53. PubMed ID: 12691863
[TBL] [Abstract][Full Text] [Related]
44. Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients.
Fonseca R; Trendle MC; Leong T; Kyle RA; Oken MM; Kay NE; Van Ness B; Greipp PR
Br J Haematol; 2000 Apr; 109(1):24-9. PubMed ID: 10848778
[TBL] [Abstract][Full Text] [Related]
45. Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density.
Halleen JM; Ylipahkala H; Alatalo SL; Janckila AJ; Heikkinen JE; Suominen H; Cheng S; Väänänen HK
Calcif Tissue Int; 2002 Jul; 71(1):20-5. PubMed ID: 12073156
[TBL] [Abstract][Full Text] [Related]
46. Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy-and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer.
Tähtelä R; Thölix E
Anticancer Res; 1996; 16(4B):2289-93. PubMed ID: 8694558
[TBL] [Abstract][Full Text] [Related]
47. TRACP 5b and CTX as osteological markers of delayed fracture healing.
Moghaddam A; Müller U; Roth HJ; Wentzensen A; Grützner PA; Zimmermann G
Injury; 2011 Aug; 42(8):758-64. PubMed ID: 21168135
[TBL] [Abstract][Full Text] [Related]
48. Plasma acid and alkaline phosphatase in patients with breast cancer.
Nguyen M; Bonneterre J; Hecquet B; Desoize B; Demaille A
Anticancer Res; 1991; 11(2):831-3. PubMed ID: 2064338
[TBL] [Abstract][Full Text] [Related]
49. Tartrate-resistant acid phosphatase 5b and its correlations with other markers of bone metabolism in kidney transplant recipients and dialyzed patients.
Małyszko J; Małyszko JS; Pawlak K; Wołczyński S; Myśliwiec M
Adv Med Sci; 2006; 51():69-72. PubMed ID: 17357281
[TBL] [Abstract][Full Text] [Related]
50. Tartrate-resistant acid phosphatase 5b is a useful serum marker for extensive bone metastasis in breast cancer patients.
Chao TY; Yu JC; Ku CH; Chen MM; Lee SH; Janckila AJ; Yam LT
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):544-50. PubMed ID: 15701839
[TBL] [Abstract][Full Text] [Related]
51. Serum levels of procollagen type I carboxyterminal extension peptide in cancer patients with bone metastases.
Santi I; Monti M; Viganò A; D'Aprile E; Rampoldi E; Castellani L; Accinni R; Cunietti E
Int J Biol Markers; 1995; 10(2):107-12. PubMed ID: 7561234
[TBL] [Abstract][Full Text] [Related]
52. Collagen derived serum markers in carcinoma of the prostate.
Rudnicki M; Jensen LT; Iversen P
Scand J Urol Nephrol; 1995 Sep; 29(3):317-21. PubMed ID: 8578275
[TBL] [Abstract][Full Text] [Related]
53. Potential role of tartrate-resistant acid phosphatase 5b (TRACP 5b) as a surrogate marker of late loosening in patients with total hip arthroplasty: a cohort study.
Savarino L; Avnet S; Greco M; Giunti A; Baldini N
J Orthop Res; 2010 Jul; 28(7):887-92. PubMed ID: 20063383
[TBL] [Abstract][Full Text] [Related]
54. Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption.
Hannon RA; Clowes JA; Eagleton AC; Al Hadari A; Eastell R; Blumsohn A
Bone; 2004 Jan; 34(1):187-94. PubMed ID: 14751577
[TBL] [Abstract][Full Text] [Related]
55. Alternative immunoassay for tartrate-resistant acid phosphatase isoform 5b using the fluorogenic substrate naphthol ASBI-phosphate and heparin.
Janckila AJ; Simons RM; Yam LT
Clin Chim Acta; 2004 Sep; 347(1-2):157-67. PubMed ID: 15313154
[TBL] [Abstract][Full Text] [Related]
56. Tartrate-resistant acid phosphatase 5b and C-terminal telopeptides of type I collagen as markers for diagnosis of aseptic loosening after total hip replacement.
Landgraeber S; Löer F; Heep H; Classen T; Grabellus F; Totsch M; von Knoch M
Arch Orthop Trauma Surg; 2010 Apr; 130(4):441-5. PubMed ID: 19513735
[TBL] [Abstract][Full Text] [Related]
57. Clinical value of serum bone resorption markers for predicting clinical outcomes after use of bone modifying agents in metastatic bone tumors: A prospective cohort study.
Urakawa H; Ando Y; Hase T; Kikumori T; Arai E; Maeda O; Mitsuma A; Sugishita M; Shimokata T; Ikuta K; Ishiguro N; Nishida Y
Int J Cancer; 2020 Jun; 146(12):3504-3515. PubMed ID: 31846063
[TBL] [Abstract][Full Text] [Related]
58. [A possibility of the prognosis factor of serum cross-linked carboxyterminal telopeptide region of type I collagen (ICTP) as a marker of bone metastasis].
Yagi Y; Yoneda M; Okada M; Omoto A; Nakamura M
Kaku Igaku; 2002 Nov; 39(4):485-91. PubMed ID: 12607236
[TBL] [Abstract][Full Text] [Related]
59. Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis.
Chu P; Chao TY; Lin YF; Janckila AJ; Yam LT
Am J Kidney Dis; 2003 May; 41(5):1052-9. PubMed ID: 12722040
[TBL] [Abstract][Full Text] [Related]
60. Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption.
Halleen JM; Tiitinen SL; Ylipahkala H; Fagerlund KM; Väänänen HK
Clin Lab; 2006; 52(9-10):499-509. PubMed ID: 17078477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
